TIDMLLAI

RNS Number : 9096N

LungLife AI, INC

28 September 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

Clinical validation study update

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company's clinical validation study for its LungLB(R) test.

As stated in the Company's half-year report on 8 August 2023, LungLife is currently focussed on preparing data from the clinical validation study for detailed analysis, which was expected to be concluded by the end of September 2023. Due to delays in the provision of data from study sites, full database lock, and the consequent knock-on impact on ability to analyse the data we now expect this to be concluded in Q4 2023.

For further information please contact:

 
LungLife AI, Inc.                                                            www.lunglifeai.com 
Paul Pagano, CEO                                                                Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                   Tel: +44 (0)20 7597 5970 
 & Joint Broker) 
Virginia Bull / Cameron MacRitchie 
 / Lydia Zychowska 
 
Goodbody (Joint Broker)                                    Tel: +44 (0) 20 3841 6202 / +353 (1) 
 Tom Nicholson / Stephen Kane                                                          667 0420 
Walbrook PR Limited                       Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings / Phillip                    Mob: 07980 541 893 / 07407 804 654 / 
 Marriage                                                                         07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESLRMLTMTMTBFJ

(END) Dow Jones Newswires

September 28, 2023 02:00 ET (06:00 GMT)

Lunglife Ai (LSE:LLAI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Lunglife Ai.
Lunglife Ai (LSE:LLAI)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Lunglife Ai.